… neoadjuvant regimen in patients with EGFR-mutant … neoadjuvant therapy regimen based
on their EGFR status. Our study represents a foundation for the use of erlotinib in neoadjuvant …

… of neoadjuvant EGFR-TKI for treatment of EGFR-mutant NSCLC… resectable EGFR-mutant
NSCLC treated with neoadjuvant … a more effective neoadjuvant targeted therapy regimen given …

… plasma samples for central EGFR mutation analysis will be … 1 day 1 of the neoadjuvant period,
the presurgical assessment (… cells (identified by routine hematoxylin and eosin staining) in …

… regimens in the neoadjuvant setting. The phase 2 ASCENT trial reported the results of
neoadjuvant afatinib in patients with stage III EGFR-mutant … Eight weeks of neoadjuvant afatinib …

… field of stage IIIA epidermal growth factor receptor (EGFR) mutation-… and safety of neoadjuvant
targeted therapy (NTT) with neoadjuvant … setting, there is still controversy about the routine …

… feasibility of biomarker-guided neoadjuvant therapy among patients with N2 NSCLC receiving
TKI or chemotherapy as neoadjuvant regimen based on EGFR mutation status. The RR …

… plus cisplatin (GC chemotherapy) as neoadjuvant/adjuvant therapy in patients with …
EGFR mutations in exon 19 or 21 (EMERGING). Patients received erlotinib 150 mg/d (neoadjuvant …

… that first-line EGFR-TKI regimen can improve tumor response … by different biological features
of EGFR mutant and wild type … and proof to validate efficacy of TKI neoadjuvant therapy. …

… Thus, we analyzed the association between EGFR mutation and … received neoadjuvant CRT
followed by surgical resection. … The chemotherapy regimens consisted of weekly paclitaxel (…

… higher with neoadjuvant targeted therapy than with chemotherapy among patients harboring
EGFR mutation [objective response rate (ORR): 55.8% vs. 32.6%; P= 0.030]. EGFR exon 19 …